A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure

Overview of attention for article published in JACC: Basic to Translational Science, December 2016

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#10 of 831)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 5 public wall posts from 5 users.

Editors' Insights: Is Cimaglermin Alfa potentially a novel therapy for systolic heart failure? Read more about this first-in-huma…

Can Cimerglermin Alfa improve EF in systolic heart failure? #JACCBTS #openaccess #research http://ow.ly/Yqo2307GDxx pic.twitter.

Editors' Insights: Is Cimaglermin Alfa potentially a novel therapy for systolic heart failure? Read more about this first-in-huma…

• Cimaglermin is a recombinant neuregulin that appears to be important for essential cardiac repair processes.

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity, including 1 additional Facebook posts.